North America Cardiac Biomarkers Market Size & Outlook

The cardiac biomarkers market in North America is expected to reach a projected revenue of US$ 22,016.5 million by 2033. A compound annual growth rate of 11.9% is expected of North America cardiac biomarkers market from 2026 to 2033.
Revenue, 2025 (US$M)
$9,015.2
Forecast, 2033 (US$M)
$22,016.5
CAGR, 2026 - 2033
11.9%
Report Coverage
North America

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America cardiac biomarkers market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America cardiac biomarkers market highlights

  • The North America cardiac biomarkers market generated a revenue of USD 9,015.2 million in 2025.
  • The market is expected to grow at a CAGR of 11.9% from 2026 to 2033.
  • In terms of segment, troponin was the largest revenue generating type in 2025.
  • Troponin is the most lucrative type segment registering the fastest growth during the forecast period.
  • Country-wise, U.S. is expected to register the highest CAGR from 2026 to 2033.


North America data book summary

Market revenue in 2025USD 9,015.2 million
Market revenue in 2033USD 22,016.5 million
Growth rate11.9% (CAGR from 2026 to 2033)
Largest segmentTroponin
Fastest growing segmentTroponin
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationCK-MB, Myoglobin, Troponin, BNP and NT-proBNP
Key market players worldwideAbbott Laboratories, QuidelOrtho Corp, Siemens Healthineers AG ADR, Roche Holding AG ADR, Danaher Corp, BioMerieux SA, Bio-Rad Laboratories Inc, Randox, Creative Diagnostics, Life Diagnostics


Other key industry trends

  • In terms of revenue, North America region accounted for 43.3% of the global cardiac biomarkers market in 2025.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 12,660.4 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cardiac Biomarkers Market Companies

Name Profile # Employees HQ Website
Life Diagnostics View profile 1-10 West Chester, Pennsylvania, United States, North America http://lifediagnostics.com
Randox View profile 1001-5000 Crumlin, Antrim, United Kingdom, Europe http://www.randox.com
Creative Diagnostics View profile 51-100 New York, New York, United States, North America http://www.creative-diagnostics.com
Bio-Rad Laboratories Inc View profile 8030 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 https://www.bio-rad.com
QuidelOrtho Corp View profile 7100 9975 Summers Ridge Road, San Diego, CA, United States, 92121 https://www.quidelortho.com
Danaher Corp View profile 63000 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 https://www.danaher.com
Siemens Healthineers AG ADR View profile 71400 Siemensstr. 3, Forchheim, BY, Germany, 91301 https://www.siemens-healthineers.com
BioMerieux SA View profile 13982 Marcy l’Etoile, Lyon, France, 69280 http://www.biomerieux.com
Abbott Laboratories View profile 114000 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 https://www.abbottinvestor.com
Roche Holding AG ADR View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com

North America cardiac biomarkers market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac biomarkers market will help companies and investors design strategic landscapes.


Troponin was the largest segment with a revenue share of 40.27% in 2025. Horizon Databook has segmented the North America cardiac biomarkers market based on ck-mb, myoglobin, troponin, bnp and nt-probnp covering the revenue growth of each sub-segment from 2021 to 2033.


North America is estimated to dominate the cardiac biomarkers market. Cardiac diseases have been identified as the leading cause of mortality among the U.S. citizens. According to recent statistics from the U.S. Centers for Disease Control and Prevention (CDC), CVDs account for 610,000 deaths in the U.S every year. 

The fatality from heart diseases has been deemed to be high in North America. Cardiovascular diseases present a huge socioeconomic burden to the people of the United States, which has enlarged the demand for cardiac disease diagnostics. 

In response to this high demand, the cardiac biomarkers field, which comprises prime indicators of fatal heart diseases, such as acute myocardial infarction and congestive heart failure is expected to grow. After the implementation of the Affordable Care Act, Medicaid coverage has grown significantly.

Reasons to subscribe to North America cardiac biomarkers market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America cardiac biomarkers market databook

  • Our clientele includes a mix of cardiac biomarkers market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America cardiac biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into North America cardiac biomarkers market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

North America cardiac biomarker market size, by country, 2021-2033 (US$M)

North America Cardiac Biomarkers Market Outlook Share, 2025 & 2033 (US$M)

North America cardiac biomarker market size, by country, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online